Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II
study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no
targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based
standard-combination chemotherapy but eligible for at-least mono-chemotherapy with
gemcitabine or vinorelbine.